Skip to content
OpenCapital
Get started

Sarepta Therapeutics, Inc. SRPT Pre-tax stock-based compensation cost

Pre-tax stock-based compensation cost at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
——

Segments

By segment

See full
All Other Segments$29.4M-29.0%

Other financials

Income statement

See full
Revenue$730.8M-1.9%
Operating income-$300.4M-961%
Net income$331.0M+174%
EPS (diluted)-$4.60-1,343%

Balance sheet

See full
Cash & equivalents$464.5M+92.8%
Total debt$198.5M-3.4%
Total equity$1.5B+31.7%
Total assets$3.2B-8.3%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$2.1M-95.2%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.76B-63.1%

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin4.6%+2.4pp
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-23.6%-28.5pp
Debt / equity0.1×0.0×
Current ratio4.6×+0.6×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s pre-tax stock-based compensation cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s pre-tax stock-based compensation cost?
Sarepta Therapeutics, Inc. (SRPT) reported pre-tax stock-based compensation cost of $29.4M in Q1 2026.
How has Sarepta Therapeutics, Inc.'s pre-tax stock-based compensation cost changed year-over-year?
Sarepta Therapeutics, Inc.'s pre-tax stock-based compensation cost decreased by 29.0% year-over-year, from $41.4M to $29.4M.